Turnstone Biologics Corp. (TSBX) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Low Risk
Limited dilution potential
Last updated: May 09, 2025

Risk Assessment Details

Potential Dilution: 0.0% of current shares
Recent Dilution: 0.44% (2 years)
Historical Dilution Factor: minimal recent dilution
Outstanding Shares
23M
Potential Supply
0
Additional shares possible
Splits
None
Past 2 years

Summary

TSBX currently has 23.1M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 0.44% over the past 2 years.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 09, 2025

10-Q filing | 23.1M shares outstanding

23M 0
Mar 31, 2025

10-K filing | 23.0M shares outstanding

23M 0
Nov 12, 2024

10-Q filing | 23.0M shares outstanding

23M 0
Aug 14, 2024

10-Q filing | 23.0M shares outstanding

23M 0
May 13, 2024

10-Q filing | 23.0M shares outstanding

23M 0
Mar 22, 2024

10-K filing | 23.1M shares outstanding

23M 0
Nov 13, 2023

10-Q filing | 23.1M shares outstanding

23M 0
Sep 01, 2023

10-Q filing | 22.8M shares outstanding

23M 0
Jul 17, 2023

S-1/A filing: This S-1/A filing discusses voting rights, liquidation preferences, rights and preferences of common stockholders, potential conflicts of interest, and the possibility of stock price decline due to substantial sales of common stock. It also mentions Takeda's non-binding indication of interest to purchase shares in the offering and lock-up agreements.

21M 0
Jun 26, 2023

S-1/A filing: This S-1/A filing discusses voting rights, liquidation preferences, and rights and preferences of common stock holders. It also mentions an option for underwriters to purchase additional shares and restrictions on sales of similar securities by the company and its insiders for 180 days.

N/A 0
Jun 12, 2023

S-1 filing: This is an S-1 filing detailing voting rights, liquidation preferences, and restrictions on the sale of common stock by insiders for 180 days after the prospectus date, with exceptions for certain transfers. It also mentions an option for underwriters to purchase additional shares.

N/A 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime